JPMorgan Raises Edgewise Therapeutics Price Target to $45 on Pipeline Confidence

AI Summary

JPMorgan increased the price target for Edgewise Therapeutics, Inc. (EWTX) from $34 to $45 while maintaining an Overweight rating. This reflects optimism regarding the EDG-7500 pipeline and the upcoming release of 12-week data in Q2 2026, which may impact the outlook for EDG-7500. Additionally, long-term results from a study on sevasemten showed that patients maintained stable functional abilities over 3.5 years. The company also plans to present data from the GRAND CANYON pivotal cohort in Q4 2026, potentially aiding in regulatory approval for sevasemten.